Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy

NCT ID: NCT02984813

Last Updated: 2021-03-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-04-15
• Study Completion Date: 2017-01-15

Brief Summary

This study is a multi-armed protocol designed to evaluate the safety and efficacy of two different combinations of nutritional supplements (study drug) (Glauco-Health and Glauco-Select) chosen for their potential to protect retinal ganglion cells against oxidative stress, low-grade inflammation, and mitochondrial dysfunction in patients with open-angle glaucoma and diabetic retinopathy. Oxidative stress and retinal cellular dysfunction will be measured using a Retinal Metabolic Analyzer (RMA) in this randomized, single center, double masked study. Patients with glaucoma will be divided into three treatment arms randomized to receive either Glauco-Health, Glauco-Select, or placebo.

Detailed Description

This investigation is using over the counter supplements. The investigation is intended only to evaluate their effect on the structure or function of mitochondria as it relates to the autofluorescence imaging being conducted in the study. They are not being studied to evaluate their ability to diagnose, cure, mitigate, or treat disease.

These ingredients in these combinations of nutritional supplements have also been reported beneficial in diabetic retinopathy. Patients with diabetic retinopathy will be added later as an additional arm and an amendment to this effect will be submitted when that portion of the study is ready to be initiated. That amendment will include background material, appropriate inclusion and exclusion criteria, informed consent, and references. At the current time, only the glaucoma proposal and glaucoma patients will be enrolled according to this submitted protocol.

Conditions

Open-angle Glaucoma; Diabetic Retinopathy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

GlaucoHealth

2 pills once daily in the morning for 3 months

Group Type: EXPERIMENTAL

GlaucoHealth

Intervention Type: DRUG

Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract

GlaucoSelect

2 pills once daily in the morning for 3 months

Group Type: EXPERIMENTAL

GlaucoSelect

Intervention Type: DRUG

Containing curcumin, bilberry extract, and grape seed extract

Placebo

2 pills once daily in the morning for 3 months

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

No active ingredients

Interventions

GlaucoHealth

Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract

Intervention Type: DRUG

GlaucoSelect

Containing curcumin, bilberry extract, and grape seed extract

Intervention Type: DRUG

Placebo

No active ingredients

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female of any race, at least 18 years of age.

2. Has provided verbal and written informed consent.

3. Able and willing to follow instructions, including participation in all study assessments and visits.

4. Eyes with moderate to severe primary open-angle glaucoma will be enrolled. Glaucoma severity will be graded using the WHO glaucoma staging system.

1. OAG eyes are defined by clinical findings consistent with glaucomatous optic neuropathy (Ex: thinning, excavation, rim erosion or notching of the neuroretinal rim)

2. Reproducible visual field defects on at least three examinations as measured by a glaucoma hemifield test (GHT) result outside normal limits and/or the presence of at least three consecutive test points on the pattern deviation plot with P<1% and at least one at P<0.05%, not including points on the edge of the field.

5. Both eyes will be enrolled.

6. Refractive error ≤5 diopters and astigmatism ≤3 diopters

Exclusion Criteria

1. Comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assignment, such as age-related macular degeneration, macular dystrophy, retinopathy from systemic diseases, marked ocular media opacities that obscure retinal imaging, etc.

2. BCVA <20/200

3. Concurrent conjunctivitis, keratitis or uveitis

4. History of penetrating ocular trauma.

5. Subject uncooperativeness that restricts adequate examination of IOP, ocular fundus or anterior chamber.

6. Has a condition or history that, in the opinion of the investigator, may interfere significantly with the subject's participation in the study.

7. A woman who is pregnant, nursing an infant, or planning a pregnancy

8. Has a known adverse reaction and/or sensitivity to the study drug or its compound.

a. Including: alpha lipoic acid, citicoline, Co-enzyme Q-10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, green tea extract, and bilberry extract.

9. Currently enrolled in an investigational drug study or has used an investigational drug within 30 days prior to Visit 1.

10. Is planning on having surgery at any time throughout the study duration (90 days from initiation)

11. Is currently receiving chemotherapy

12. Has a history of diabetes mellitus, seizure(s), bleeding disorder(s)

13. Has a history of uncontrolled hypertension (≥180 systolic or ≥110 diastolic on two successive measures)

14. Has a history of any radiation around the eyes

15. Currently using anticoagulant/antiplatelet drugs (patients on coumadin, clopidogral (Plavix), and plasugrel (Effient) will be excluded but that patients taking aspirin will be allowed)

16. Unwilling or unable to cease using other anti-oxidative agents or drugs.

17. Dilated pupil diameter less than 5 millimeters

18. Fluorescein drop administration within 8 hours before imaging

19. History of cataract surgery in the 3 months prior to imaging

20. History of any other intraocular surgery within 4 months prior to enrollment

21. Corticosteroid or immunosuppressive therapy within 6-months prior to imaging

22. Lens opacity ≥grade 3 on ARLNS on standard photographs (Appendix 6)

23. History of vitrectomy

24. Monocular patients

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The New York Eye & Ear Infirmary

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robert Ritch, MD

Role: PRINCIPAL_INVESTIGATOR

Shelley and Steven Einhorn Distinguished Chair Professor of Ophthalmology Surgeon Director Emeritus and Chief, Glaucoma Services The New York Eye and Ear Infirmary of Mount Sinai

Locations

New York Eye and Ear Infirmary of Mount Sinai

New York, New York, United States

Countries

United States

Other Identifiers

15.25

Identifier Type: -

Identifier Source: org_study_id